Mizuho raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $39 from $32 and keeps an Outperform rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Advances CRB-701 Clinical Study for Solid Tumors
- Corbus Pharmaceuticals’ CRB-601 Study: A New Hope for Advanced Solid Tumors
- Corbus Pharmaceuticals Presents Promising CRB-701 Study Results
- Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler
- Promising Trial Results and Market Potential Drive Buy Rating for Corbus Pharmaceuticals’ CRB-701